BioCentury
ARTICLE | Clinical News

APC 366: To begin a Phase I trial in the U.K. in January

December 20, 1993 8:00 AM UTC

Arris Pharmaceutical Corp. (ARRS) Product: APC 366, small molecule that blocks mast cell-mediated inflammation Indication: Asthma Status: To begin a Phase I trial in the U.K. in January ...